Gosset Antigen presentation by human leukocyte antigen molecule Overview
The process described—"Immune system stimulation via presentation of tumor-associated antigen-derived synthetic long peptides on HLA molecules leading to activation of T cells"—refers not to a single molecular target but rather to a biological mechanism central to cancer immunotherapy. In this mechanism, **human leukocyte antigen (HLA) molecules** present peptides derived from tumor-associated antigens on the surface of cells. These peptides can be naturally processed or synthetically designed (as in cancer vaccines using synthetic long peptides). The presented peptide-HLA complexes are recognized by T cell receptors (TCRs) on cytotoxic CD8+ or helper CD4+ T cells, leading to immune activation against tumor cells[1][3][4]. There are two main classes involved: - **HLA class I molecules** present endogenous antigens (including those from tumors) primarily to CD8+ cytotoxic T lymphocytes. - **HLA class II molecules** present exogenous antigens mainly to CD4+ helper T cells. Synthetic long peptides can be designed for optimal processing and cross-presentation by professional antigen-presenting cells such as dendritic cells, enhancing anti-tumor immunity[1][3]. This process is foundational for many therapeutic cancer vaccines and adoptive cellular therapies. However, this entry is not a canonical molecular target like a receptor or enzyme; it describes an immunological pathway involving multiple proteins and steps. Therefore: - It is not considered a single "therapeutic target" but rather an immunological process. - There is no standard abbreviation or alias that refers specifically and exclusively to this entire mechanism. - No direct interacting drugs exist for the "target," though many immunotherapies exploit this pathway indirectly. If you seek structured information about specific components within this pathway—such as "Human leukocyte antigen class I molecule," "Transporter associated with antigen processing," or individual tumor-associated antigens—those would be valid canonical targets with more specific entries[1][3].
Mechanism of Action
Biological Functions
Disease Associations
Safety Considerations
No safety concerns listed